Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REGORAFENIB AFTER FAILURE OF GEMCITABINE AND PLATINUM-BASED CHEMOTHERAPY FOR LOCALLY ADVANCED (NON RESECTABLE) AND METASTATIC INTRA-HEPATIC OR HILAR CHOLANGIOCARCINOMA: A Randomized Double-blinded Phase II Trial.

NCT02162914 is registered in ClinicalTrials.gov with Erasme University Hospital as lead sponsor.

NCT NCT02162914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02162914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REGORAFENIB AFTER FAILURE OF GEMCITABINE AND PLATINUM-BASED CHEMOTHERAPY FOR LOCALLY ADVANCED (NON RESECTABLE) AND METASTATIC INTRA-HEPATIC OR HILAR CHOLANGIOCARCINOMA: A Randomized Double-blinded Phase II Trial.
Lead sponsor
Erasme University Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
March 14, 2014
Completion date
December 31, 2020
Enrollment
66 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma